News
The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. LONDON (AP) — The ...
11h
DPA International on MSNEMA recommends approval of additional Alzheimer's treatmentThe European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.
Sarepta Therapeutics suffered another major setback on Friday as Europe's drug regulator decided not to recommend the ...
Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...
8h
TipRanks on MSNEurope Grants Limited Approval to Eli Lilly’s (LLY) Alzheimer’s DrugBut now, after re-examining the drug at the request of Eli Lilly, the medicines committee has recommended granting Kisunla ...
The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.
The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...
European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.
The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side ...
Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group ...
Preliminary data from clinical trials of tecovirimat as a treatment for mpox virus infection have given disappointing results ...
Despite a new setback for Elevidys in Europe, Roche—which markets Sarepta’s gene therapy outside the U.S.—remains committed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results